According to Stock Market Ratings, the eleven analysts that are now following Allogene Therapeutics, Inc. (NASDAQ:ALLO) have recommended shares of the firm on average as “Moderate Buy.” Eight research experts have recommended that the business purchase the stock, while three have rated it with a hold rating. Brokers that have covered the stock over the past year have an average 12-month price objective of $15.29.
Recent comments on ALLO have come from a number of brokerages. In a research report released on Friday, January 19, HC Wainwright lowered their price target on Allogene Therapeutics shares from $12.00 to $10.00 and established a “buy” rating for the business. On Friday, January 5, JMP Securities reiterated its “market perform” recommendation for Allogene Therapeutics’ stock in a research note. Friday, December 8th marked the start of Citigroup’s research study covering shares of Allogene Therapeutics. They gave the business a “buy” rating and a $7.00 price target. In a research report released on Friday, January 5, Guggenheim reduced Allogene Therapeutics’ shares from a “buy” recommendation to a “neutral” one.
Also Read: When Is The Business Tax Filing Due for 2024?
Allogene Therapeutics: Insider Purchasing and Selling
In other Allogene Therapeutics news, on Monday, December 18, Director Deborah M. Messemer sold 18,640 shares of the company’s stock. A total of $50,328.00 was exchanged for the stock at an average price of $2.70. The director now directly owns 62,456 shares of the company, valued at about $168,631.20, as a result of the transaction. The SEC has made the sale public in a document that may be seen by clicking this URL. Insiders of the corporation hold 27.40 percent of the stock.
Expert Opinion Regarding Allogene Therapeutics: Institutional Investors
Hedge funds have adjusted their stakes in the company lately. During the second quarter, Oppenheimer & Co. Inc. invested $62,000 in new Allogene Therapeutics shares. In the second quarter, JPMorgan Chase & Co. increased its investment in Allogene Therapeutics by 22.1%. After purchasing 1,109,851 more shares of the company’s stock during the quarter, JPMorgan Chase & Co. now owns 6,134,395 shares valued at $30,488,000. In the second quarter, TD Asset Management Inc. increased its investment in Allogene Therapeutics by 14.9%. After purchasing 25,800 more shares of the company’s stock during the quarter, TD Asset Management Inc. now has 199,479 shares valued at $991,000. In the second quarter, Crosspoint Financial LLC acquired a new interest in Allogene Therapeutics for about $60,000. Lastly, in the third quarter, Harbour Capital Advisors Inc. increased its investment in Allogene Therapeutics by 18.0%. After purchasing an additional 10,473 shares of the company’s stock during the quarter, Harbour Capital Advisors Inc. now owns 68,519 shares valued at $217,000. Institutional investors now hold 78.51% of the stock.
Also Read: 2024 to bring some major changes filing taxes
Allogene Therapeutics Price Performance: NASDAQ ALLO’s shares opened Friday at $3.24. The 50-day simple moving average of the firm is $2.92, while the 200-day simple moving average is $3.47. With a market value of $545.23 million, the company has a -1.45 PE ratio and a 0.76 beta. In the past year, Allogene Therapeutics has seen lows of $2.23 and highs of $8.44.
The most recent quarterly earnings data for Allogene Therapeutics (NASDAQ:ALLO) were disclosed on Thursday, November 2. The firm exceeded the average expectation of ($0.53) by $0.16 when it announced ($0.37) earnings per share (EPS) for the quarter. Allogene Therapeutics had a 54.03% negative return on equity and a 178,954.28% negative net margin. In contrast to analyst projections of $0.05 million, the company’s revenue for the quarter was $0.04 million. Research analysts collectively predict that Allogene Therapeutics’ earnings per share for the current fiscal year will be -2.03.
Concerning Allogene Therapeutics
Genetically modified allogeneic T cell treatments are developed and marketed by Allogene Therapeutics, Inc., a clinical stage immuno-oncology business, to treat cancer. It creates, produces, and markets UCART19, a potential allogeneic chimeric antigen receptor (CAR) T cell therapy for treating adult and paediatric R/R CD19 positive B-cell ALL patients.
Is it currently a good time to buy $1,000 in Allogene Therapeutics?
You should know this before thinking about Allogene Therapeutics.
Every day, Wall Street’s top-rated and top-performing research analysts and the companies they advise to their customers are monitored. Allogene Therapeutics was not included in the list of the five stocks that leading analysts are subtly advising their customers to purchase before the market as a whole catches on.
Although analysts now rank Allogene Therapeutics as a “Moderate Buy,” they think these five companies are better investments.
Source:
https://www.marketbeat.com/instant-alerts/nasdaq-allo-consensus-analyst-rating-2024-01-28/
-
Krispy Kreme’s Ghostbusters Doughnut Collection – A Spooky Collaboration for 2024
Krispy Kreme has always been known for its creative and exciting limited-edition doughnuts, and this October, the company has outdone itself once again. In celebration of the 40th anniversary of the cult-classic movie Ghostbusters, Krispy Kreme has launched a new collection of doughnuts inspired by the beloved film, offering fans a deliciously spooky treat that…
-
Ticketmaster to Pioneer New Apple Wallet Ticketing Feature on iOS 18
As the world anticipates the release of iOS 18, Apple has unveiled a revolutionary enhancement to its Apple Wallet—a feature that promises to transform the ticketing industry. Leading the charge is Ticketmaster, which is set to be the first major ticketing platform to implement this new feature. This collaboration between Apple and Ticketmaster will offer…
-
Breaking News – Addison’s Disease Rare Condition Affecting the Adrenal Glands
October 2024 – Addison’s disease, also known as primary adrenal insufficiency, is a rare yet serious condition that occurs when the adrenal glands fail to produce sufficient levels of cortisol and aldosterone. This hormonal imbalance can have a profound effect on various bodily functions, and without timely diagnosis and treatment, the disease can become life-threatening.…
-
Addison’s Disease – Rare Endocrine Disorder and Recent Advances in Treatment
Addison’s disease, also known as primary adrenal insufficiency, is a rare but potentially life-threatening condition caused by damage to the adrenal glands, which results in insufficient production of essential hormones such as cortisol and aldosterone. First identified by British physician Thomas Addison in 1855, this disorder can affect people of all ages, though it remains…
-
Northern Lights Forecast: Spectacular Aurora Expected Tonight
Tonight could offer a rare and stunning display of the Northern Lights, or Aurora Borealis, visible across several parts of the U.S. due to a severe geomagnetic storm forecasted by the National Oceanic and Atmospheric Administration (NOAA). This storm, rated G4 on a scale from G1 (minor) to G5 (extreme), is the result of a…
-
WWE Bad Blood 2024: Everything You Need to Know – Date, India Timings, Full Match Card, and How to Watch
WWE fans across the globe are eagerly awaiting the return of one of the most iconic pay-per-view events, WWE Bad Blood, which makes its triumphant comeback after two decades. Here’s everything you need to know about WWE Bad Blood 2024, including the match card, viewing options, and key event details. Event Overview Date: WWE Bad…
-
UNLV vs Syracuse Football Thriller – October 4, 2024
In a dramatic showdown on October 4, 2024, the Syracuse Orange narrowly defeated the UNLV Rebels 44-41 in overtime at Allegiant Stadium, Las Vegas. Both teams entered the game with matching 4-1 records, and the contest lived up to the hype with high-paced scoring and critical plays. First Quarter: Syracuse Takes Early Lead Syracuse took…
-
Joker 2’s Rotten Tomatoes Score: A Disappointing Turn for the Sequel?
Joker: Folie à Deux, the highly anticipated sequel to 2019’s Joker, has landed with less than stellar reviews, leaving fans and critics divided. Despite initial excitement, the Rotten Tomatoes score for the movie has raised concerns about its overall impact and reception. As of early October 2024, Joker 2 holds a disappointing Rotten Tomatoes score…
Dwayne Paschke specializes in writing, management, development, design and Search Engine Optimization. Although he has worked for 8 years in the industry, he never found an ideal person to work with as a partner. Later, he found Sebastian Pearson, and they both found specific understanding between them. Both of them divided their tasks in this project and are running this venture successfully.